Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$157.18
-0.8%		$175.25
$145.79
▼
$212.71
$243.78B0.262.74 million shs3.60 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.47
+0.3%		$51.91
$38.63
▼
$61.69
$102.08B0.364.63 million shs2.69 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$135.58
+2.0%		$124.94
$77.58
▼
$135.68
$334.49B0.1910.70 million shs8.89 million shs
Novartis AG stock logo
NVS
Novartis
$151.86
-0.3%		$153.61
$120.78
▼
$170.46
$289.76B0.451.96 million shs1.52 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-0.34%-2.03%-6.86%-14.47%+4.95%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-1.41%-2.47%-3.88%-1.25%+31.46%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+2.11%+3.72%+7.40%+17.57%+65.77%
Novartis AG stock logo
NVS
Novartis
-1.46%-1.46%-0.65%+1.67%+27.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$157.18
-0.8%		$175.25
$145.79
▼
$212.71
$243.78B0.262.74 million shs3.60 million shs
GSK PLC Sponsored ADR stock logo
GSK
GSK
$50.47
+0.3%		$51.91
$38.63
▼
$61.69
$102.08B0.364.63 million shs2.69 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$135.58
+2.0%		$124.94
$77.58
▼
$135.68
$334.49B0.1910.70 million shs8.89 million shs
Novartis AG stock logo
NVS
Novartis
$151.86
-0.3%		$153.61
$120.78
▼
$170.46
$289.76B0.451.96 million shs1.52 million shs
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-0.34%-2.03%-6.86%-14.47%+4.95%
GSK PLC Sponsored ADR stock logo
GSK
GSK
-1.41%-2.47%-3.88%-1.25%+31.46%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+2.11%+3.72%+7.40%+17.57%+65.77%
Novartis AG stock logo
NVS
Novartis
-1.46%-1.46%-0.65%+1.67%+27.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.73
Moderate Buy$211.0034.24% Upside
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.10
Hold$53.005.02% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$135.50-0.06% Downside
Novartis AG stock logo
NVS
Novartis
2.31
Hold$141.20-7.02% Downside

Current Analyst Ratings Breakdown

Latest GSK, MRK, NVS, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Daiwa Securities Group Inc. logo
Daiwa Securities Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Outperform$143.00
8/11/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
8/11/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$130.00 ➝ $145.00
8/5/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $146.00
7/30/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
7/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$140.00 ➝ $150.00
7/28/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/24/2026
Novartis AG stock logo
NVS
Novartis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
7/24/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral
7/22/2026
Novartis AG stock logo
NVS
Novartis
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.15$12.80 per share12.28$32.48 per share4.84
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.37$5.95 per share8.48$11.40 per share4.43
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.15$11.87 per share11.42$21.22 per share6.39
Novartis AG stock logo
NVS
Novartis
$54.53B5.31$10.55 per share14.40$21.98 per share6.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6923.5013.811.3717.02%31.45%13.20%10/30/2026 (Estimated)
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.2015.789.822.9214.56%43.23%11.60%10/28/2026 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$1.25108.4614.025.624.77%16.05%6.11%10/29/2026 (Estimated)
Novartis AG stock logo
NVS
Novartis
$13.98B$6.6322.9015.482.6523.29%38.56%14.47%10/27/2026 (Estimated)

Latest GSK, MRK, NVS, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.26-$0.13+$0.13-$0.54$16.37 billion$16.61 billion
7/27/2026Q2 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.50$2.63+$0.13$1.61$15.44 billion$15.38 billion
7/21/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
$2.17$2.41+$0.24$1.71$14.07 billion$14.41 billion
6/30/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
N/A$2.41N/A$1.71N/A$14.95 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.76%+2.30%64.87%N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.793.55%-7.86%55.94%N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.51%+5.75%272.00%14 Years
Novartis AG stock logo
NVS
Novartis
$3.082.03%+5.28%46.46%N/A

Latest GSK, MRK, NVS, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45153.36%8/14/20268/14/202610/8/2026
7/29/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.61%9/15/20269/15/202610/7/2026
5/26/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.852.96%6/15/20266/15/20267/8/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.47
0.89
0.67
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.81
0.82
0.52
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Novartis AG stock logo
NVS
Novartis
0.89
0.86
0.67

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable

Recent News About These Companies

SOA Wealth Advisors LLC. Buys 14,416 Shares of Novartis AG $NVS
August 13 at 6:50 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-soa-wealth-advisors-llc-buys-14416-shares-of-novartis-ag-nvs-2026-08-13/
Triasima Portfolio Management inc. Trims Holdings in Novartis AG $NVS
August 13 at 6:49 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-triasima-portfolio-management-inc-trims-holdings-in-novartis-ag-nvs-2026-08-13/
Novartis AG $NVS Shares Purchased by Mission Wealth Management LP
August 13 at 6:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-purchased-by-mission-wealth-management-lp-2026-08-13/
Erste Group Bank Cuts Earnings Estimates for Novartis
August 13 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30957529
Erste Group Bank Forecasts Weaker Earnings for Novartis
August 11 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/erste-group-bank-forecasts-weaker-earnings-for-novartis-2026-08-11/
Novartis AG Sponsored ADR
August 9, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/NVS
Zacks Research Comments on Novartis' Q3 Earnings (NYSE:NVS)
August 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30945193
The Manufacturers Life Insurance Company Sells 24,216 Shares of Novartis AG $NVS
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-sells-24216-shares-of-novartis-ag-nvs-2026-08-06/
Research Analysts Offer Predictions for Novartis Q3 Earnings
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/research-analysts-offer-predictions-for-novartis-q3-earnings-2026-08-05/
Segall Bryant & Hamill LLC Purchases Shares of 18,792 Novartis AG $NVS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-segall-bryant-hamill-llc-purchases-shares-of-18792-novartis-ag-nvs-2026-08-05/
Glenmede Trust Co. NA Acquires 8,680 Shares of Novartis AG $NVS
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-glenmede-trust-co-na-acquires-8680-shares-of-novartis-ag-nvs-2026-08-04/
FDA approval nearly doubles eligible patient pool for Novartis' Pluvicto
August 3, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/fda-approval-nearly-doubles-eligible-patient-pool-for-novartis-pluvicto/ar-AA29jTUP
Novartis AG $NVS Shares Sold by Public Employees Retirement System of Ohio
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-sold-by-public-employees-retirement-system-of-ohio-2026-08-03/
Henshaw Capital LLC Grows Stock Position in Novartis AG $NVS
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-henshaw-capital-llc-grows-stock-position-in-novartis-ag-nvs-2026-08-02/
FY2026 EPS Estimates for Novartis Raised by Erste Group Bank
August 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30935315
Novartis AG $NVS Shares Purchased by Royal Bank of Canada
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-purchased-by-royal-bank-of-canada-2026-08-01/
Bank of America Corp DE Raises Stock Holdings in Novartis AG $NVS
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-stock-holdings-in-novartis-ag-nvs-2026-08-01/
Erste Group Bank Forecasts Increased Earnings for Novartis
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/erste-group-bank-forecasts-increased-earnings-for-novartis-2026-07-31/
Novartis AG $NVS Shares Bought by Janus Henderson Group PLC
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-bought-by-janus-henderson-group-plc-2026-07-31/
Novartis AG $NVS Shares Bought by Empowered Funds LLC
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-bought-by-empowered-funds-llc-2026-07-31/
Arrowstreet Capital Limited Partnership Sells 679,380 Shares of Novartis AG $NVS
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-sells-679380-shares-of-novartis-ag-nvs-2026-07-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astrazeneca stock logo

Astrazeneca NYSE:AZN

$157.18 -1.32 (-0.83%)
Closing price 03:59 PM Eastern
Extended Trading
$157.52 +0.34 (+0.21%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK stock logo

GSK NYSE:GSK

$50.47 +0.17 (+0.33%)
Closing price 03:59 PM Eastern
Extended Trading
$50.46 -0.01 (-0.02%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$135.57 +2.66 (+2.00%)
Closing price 03:59 PM Eastern
Extended Trading
$135.55 -0.02 (-0.02%)
As of 06:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis stock logo

Novartis NYSE:NVS

$151.85 -0.47 (-0.31%)
Closing price 03:59 PM Eastern
Extended Trading
$151.50 -0.35 (-0.23%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas